Zhongguancun Capital
Overview
Zhongguancun Capital is a Chinese investment firm and a subsidiary of the state-owned Zhongguancun Development Group, specializing in private equity and venture capital investments across sectors such as artificial intelligence, advanced manufacturing, new energy, and healthcare.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Smorobot | Mar 2024 | Series A | Lead |
| Huahui Health Ltd. | - | Series A Extension | Co-investor |
| SineuGene Therapeutics | Aug 2024 | VC Round | Lead |
| Beijing Shuimu Dongfang Medical Technology Co., Ltd. | Jan 2019 | Angel | Co-investor |
| Beijing Zhuozhi Medical Technology Co., Ltd. | Sep 2026 | Angel | Lead |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Zhongguancun Capital based?
Zhongguancun Capital is headquartered in Beijing, China.
When was Zhongguancun Capital founded?
Zhongguancun Capital was founded in 2016.
How many portfolio companies does Zhongguancun Capital have?
Zhongguancun Capital has 5 portfolio companies in Caplight's dataset.
What are some companies in Zhongguancun Capital's portfolio?
Portfolio companies visible on Caplight include Smorobot, Huahui Health Ltd., SineuGene Therapeutics, Beijing Shuimu Dongfang Medical Technology Co., Ltd., Beijing Zhuozhi Medical Technology Co., Ltd..
What was Zhongguancun Capital's most recent investment shown here?
Zhongguancun Capital's most recent investment in this portfolio sample was in Beijing Zhuozhi Medical Technology Co., Ltd. in 2026.
What sectors does Zhongguancun Capital focus on?
Zhongguancun Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Consumer & Commerce, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech.
What company stages does Zhongguancun Capital focus on?
Zhongguancun Capital typically invests at the Early stage.
What is Zhongguancun Capital's AUM?
Zhongguancun Capital's assets under management are estimated between $7.6B and $29.0B.